Street Calls of the Week
Director Richard H Scheller disposed of 20,744 shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) common stock on September 15, 2025. The shares were sold at prices ranging from $22.14 to $22.585, for a total value of $464,034. Following the transaction, Scheller directly owns 0 shares of the company. The sale comes amid MAZE’s strong market performance, with the stock up 42% in the past week and 112% over six months. Currently trading at $23.47, the stock’s technical indicators suggest overbought conditions, while analyst targets range from $27 to $50.Want deeper insights into insider trading patterns and comprehensive technical analysis? InvestingPro offers exclusive access to 13+ additional key insights about MAZE, including detailed financial health metrics and Fair Value estimates.
In other recent news, Maze Therapeutics has seen several updates regarding its MZE782 drug candidate. The company reported promising Phase 1 data, showing significant increases in urinary phenylalanine excretion, which exceeded previous benchmarks. Following this, several analyst firms have adjusted their outlooks on Maze Therapeutics. Guggenheim raised its price target to $34, while BTIG increased it to $37, maintaining a Buy rating due to the strong data. H.C. Wainwright went further, increasing its price target from $34 to $50, citing robust pharmacodynamic signals that surpassed competitor benchmarks. Additionally, BTIG initiated coverage with a Buy rating and a $30 price target, highlighting Maze’s potential in APOL1-mediated kidney disease with its MZE829 drug candidate. These developments reflect the positive reception of Maze’s ongoing research and its potential impact on the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.